Does Stelara Work for Psoriasis?
Yes, Stelara (ustekinumab) is FDA-approved to treat moderate to severe plaque psoriasis in adults and children 6 years and older who are candidates for phototherapy or systemic therapy.[1] It targets interleukins 12 and 23, cytokines that drive inflammation in psoriasis, reducing plaques, scaling, and itching.
How Quickly Does Stelara Improve Psoriasis Symptoms?
Patients often see clearer skin within 4 weeks after the initial doses (subcutaneous injections at weeks 0, 4, then every 12 weeks). By week 12, clinical trials showed 67-76% achieving at least 75% improvement (PASI 75) versus 4% on placebo.[1][2]
Who Qualifies for Stelara Psoriasis Treatment?
It's for those with 10% or more body surface area affected, failing topical treatments, or needing biologics. Not first-line for mild cases—doctors start with topicals or phototherapy. Pediatric approval covers ages 6+ weighing at least 88 pounds.[1]
Common Side Effects Patients Report with Stelara for Psoriasis
Upper respiratory infections (around 20%), headaches, and fatigue occur most often. Serious risks include infections (e.g., tuberculosis reactivation), malignancy, and reversible posterior leukoencephalopathy syndrome. Long-term use shows no increased cancer risk in trials up to 5 years.[1][2] Patients on immunosuppressants face higher infection odds.
How Does Stelara Compare to Other Psoriasis Biologics?
| Drug | Targets | Dosing | PASI 90 at Week 12 | Key Edge |
|------|---------|--------|---------------------|----------|
| Stelara | IL-12/23 | Every 12 weeks | ~50% | Longest intervals, good for maintenance |
| Skyrizi (risankizumab) | IL-23 | Every 12 weeks | ~75% | Higher clearance rates |
| Tremfya (guselkumab) | IL-23 | Every 8 weeks | ~70% | Similar efficacy, more frequent dosing |
| Cosentyx (secukinumab) | IL-17 | Weekly then monthly | ~70% | Faster onset for some |
Stelara has broader approvals (psoriasis, psoriatic arthritis, Crohn's), but IL-17/23 inhibitors often clear skin better.[2][3]
When Does Stelara's Psoriasis Patent Expire?
Core patents expired in 2023-2025, but formulation and method-of-use patents extend to 2032-2034, with ongoing litigation from biosimilar challengers like Samsung Bioepis and Alvotech. Exclusivity ends around 2025, potentially allowing biosimilars sooner.[4]
Cost and Access for Psoriasis Patients
A 12-week course costs $25,000-$30,000 without insurance; copay cards drop it to $5/month for eligible patients. Medicare covers it, but prior authorizations require documented failures on other therapies.[1]
[1]: FDA Label - Stelara (ustekinumab). https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761044s028lbl.pdf
[2]: NEJM - Ustekinumab Phase 3 Trials (2007). https://www.nejm.org/doi/full/10.1056/NEJMoa061066
[3]: AAD Guidelines - Biologics for Psoriasis (2021). https://www.aad.org/member/clinical-quality/guidelines/psoriasis
[4]: DrugPatentWatch - Stelara Patents. https://www.drugpatentwatch.com/p/tradename/STELARA